BioXcel Therapeutics, Inc.
BTAI
$2.07
$0.168.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.91M | -19.19M | -7.25M | -10.86M | -13.65M |
| Total Depreciation and Amortization | 75.00K | 75.00K | 76.00K | 77.00K | 77.00K |
| Total Amortization of Deferred Charges | 440.00K | 393.00K | 350.00K | 222.00K | 106.00K |
| Total Other Non-Cash Items | 13.21M | 3.74M | -3.63M | -7.54M | -1.55M |
| Change in Net Operating Assets | -1.60M | 2.41M | -1.58M | 3.29M | -1.32M |
| Cash from Operations | -18.79M | -12.58M | -12.04M | -14.81M | -16.34M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -2.50M | -- |
| Issuance of Common Stock | 38.23M | 140.00K | 14.01M | 7.00M | 468.00K |
| Repurchase of Common Stock | -16.00K | 0.00 | -1.00K | -46.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -686.00K | -3.00K | -803.00K | -179.00K | -14.00K |
| Cash from Financing | 37.53M | 137.00K | 13.20M | 4.28M | 454.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.75M | -12.44M | 1.16M | -10.53M | -15.88M |